<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713709</url>
  </required_header>
  <id_info>
    <org_study_id>NP-NAL-004</org_study_id>
    <nct_id>NCT04713709</nct_id>
  </id_info>
  <brief_title>A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder</brief_title>
  <official_title>A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder and Narcan® 4 mg/0.1 mL Nasal Spray Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nasus Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nasus Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Nasal Powder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comparison between FMXIN001 4 mg and Narcan® 4 mg/0.1 mL Nasal Spray under Fasting&#xD;
      Conditions. A pharmacokinetic study in healthy volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2021</start_date>
  <completion_date type="Actual">October 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open-label, single-dose, randomized, two-period, two treatment, two-sequence, crossover, comparative bioavailability study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unconjugated naloxone in plasma - Cmax</measure>
    <time_frame>0 to 8 hours post dose</time_frame>
    <description>Pharmacokinetic Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unconjugated naloxone in plasma - AUC</measure>
    <time_frame>0 to 8 hours post dose</time_frame>
    <description>Pharmacokinetic Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unconjugated naloxone in plasma - Tmax</measure>
    <time_frame>0 to 8 hours post dose</time_frame>
    <description>Pharmacokinetic Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unconjugated naloxone in plasma - K el</measure>
    <time_frame>0 to 8 hours post dose</time_frame>
    <description>Pharmacokinetic Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unconjugated naloxone in plasma- T half</measure>
    <time_frame>0 to 8 hours post dose</time_frame>
    <description>Pharmacokinetic Parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>pre-dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>pre-dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>1 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>2 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>2 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>4 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>4 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>12 hour post dose</time_frame>
    <description>Safety Monitoring: Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECG</measure>
    <time_frame>pre-dose</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECG</measure>
    <time_frame>0.5 hours</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECG</measure>
    <time_frame>2 hours</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead ECG</measure>
    <time_frame>12 hours</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-item NHANES Pocket Smell Test</measure>
    <time_frame>pre-dose</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-item NHANES Pocket Smell Test</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal examination</measure>
    <time_frame>pre-dose</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal examination</measure>
    <time_frame>1 hour</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal examination</measure>
    <time_frame>23 hour</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0 to 24 hour post dose</time_frame>
    <description>Safety Monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Opioid Overdose</condition>
  <arm_group>
    <arm_group_label>FMXIN001 4 mg Naloxone microspheres powder,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naloxone powder nasal spray from Nasus Pharma, Israel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narcan® 4 mg/0.1 mL nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naloxone solution nasal spray from Adapt Pharma, Inc., USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Nasus Pharma FMXIN001</intervention_name>
    <description>A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device</description>
    <arm_group_label>FMXIN001 4 mg Naloxone microspheres powder,</arm_group_label>
    <arm_group_label>Narcan® 4 mg/0.1 mL nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Nasal Naloxone liquid spray</intervention_name>
    <description>A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device</description>
    <arm_group_label>FMXIN001 4 mg Naloxone microspheres powder,</arm_group_label>
    <arm_group_label>Narcan® 4 mg/0.1 mL nasal spray</arm_group_label>
    <other_name>Narcan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, non-smoking, male and female subjects, 18 years of age or older.&#xD;
&#xD;
          2. BMI ≥18 and ≤30 kg/m2.&#xD;
&#xD;
          3. Females may be of childbearing or non-childbearing potential:&#xD;
&#xD;
               -  Childbearing potential:&#xD;
&#xD;
                  o Physically capable of becoming pregnant&#xD;
&#xD;
               -  Non-childbearing potential:&#xD;
&#xD;
                    -  Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral&#xD;
                       tubal ligation); and/or&#xD;
&#xD;
                    -  Postmenopausal (no menstrual period for at least 12 consecutive months&#xD;
                       without any other medical cause).&#xD;
&#xD;
          4. Willing to use acceptable, effective methods of contraception.&#xD;
&#xD;
          5. Able to tolerate venipuncture.&#xD;
&#xD;
          6. Be informed of the nature of the study and give written consent prior to any study&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The following exclusion criteria will be assessed at screening (within 28 days prior&#xD;
             to the first drug administration):&#xD;
&#xD;
               1. Known history or presence of clinically significant neurologic, hematologic,&#xD;
                  endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or&#xD;
                  cardiovascular disease or any other condition which, in the opinion of the&#xD;
                  Investigator, would jeopardize the safety of the subject or impact the validity&#xD;
                  of the study results.&#xD;
&#xD;
               2. Known or suspected carcinoma.&#xD;
&#xD;
               3. Known history or presence of hypersensitivity or idiosyncratic reaction to&#xD;
                  naloxone or any other drug substances with similar activity.&#xD;
&#xD;
               4. Known history or presence of clinically significant lactose, galactose, or&#xD;
                  fructose intolerance.&#xD;
&#xD;
               5. Presence of hepatic or renal dysfunction.&#xD;
&#xD;
               6. Presence of nostril or septum piercing.&#xD;
&#xD;
               7. Presence of abnormal nasal anatomy.&#xD;
&#xD;
               8. Presence of hay fever/seasonal allergy/rhinitis.&#xD;
&#xD;
               9. Presence of sinusitis.&#xD;
&#xD;
              10. Presence of nasal symptoms (e.g., blocked and/or runny nose, nasal polyps).&#xD;
&#xD;
              11. Presence of nasal septum ulcers or perforations, or nasal trauma within 30 days&#xD;
                  prior to drug administration.&#xD;
&#xD;
              12. History of nasal surgery.&#xD;
&#xD;
              13. History of malabsorption within the last year or presence of clinically&#xD;
                  significant gastrointestinal disease.&#xD;
&#xD;
              14. History of atopic allergy (e.g., asthma, urticaria, eczematous dermatitis).&#xD;
&#xD;
              15. Presence of a medical condition requiring regular medication (prescription and/or&#xD;
                  over-the-counter) with systemic absorption.&#xD;
&#xD;
              16. History of drug or alcohol addiction requiring treatment.&#xD;
&#xD;
              17. Any acute illness (e.g., cold/ rhinitis, acute infection) which is considered&#xD;
                  significant by the Investigator and that has not resolved within 7 days before&#xD;
                  the first drug administration.&#xD;
&#xD;
              18. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C&#xD;
                  antibody.&#xD;
&#xD;
              19. Positive test result for urine drugs of abuse (amphetamines, barbiturates,&#xD;
                  benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and&#xD;
                  tricyclic antidepressants) or urine cotinine.&#xD;
&#xD;
              20. Difficulty fasting or consuming standard meals.&#xD;
&#xD;
              21. Inability to communicate well with the Investigators and staff (i.e., language&#xD;
                  problem, poor mental development or impaired cerebral function).&#xD;
&#xD;
              22. Use of tobacco or nicotine-containing products within 6 months prior to drug&#xD;
                  administration.&#xD;
&#xD;
              23. Females who:&#xD;
&#xD;
                    -  Have discontinued or changed the use of implanted, intrauterine,&#xD;
                       intravaginal, or injected hormonal contraceptives within 6 months prior to&#xD;
                       drug administration;&#xD;
&#xD;
                    -  Have discontinued or changed the use of oral or patch hormonal&#xD;
                       contraceptives within 1 month prior to drug administration;&#xD;
&#xD;
                    -  Are pregnant (serum hCG consistent with pregnancy); or&#xD;
&#xD;
                    -  Are lactating.&#xD;
&#xD;
              24. Donation or loss of whole blood (including clinical trials):&#xD;
&#xD;
                    -  ≥50 mL and &lt;500 mL within 30 days prior to drug administration;&#xD;
&#xD;
                    -  ≥500 mL within 56 days prior to drug administration.&#xD;
&#xD;
              25. Participation in a clinical trial that involved administration of an&#xD;
                  investigational medicinal product within 30 days prior to drug administration, or&#xD;
                  recent participation in a clinical investigation that, in the opinion of the&#xD;
                  Investigator, would jeopardize subject safety or the integrity of the study&#xD;
                  results.&#xD;
&#xD;
              26. On a special diet within 30 days prior to drug administration (e.g., liquid,&#xD;
                  protein, raw food diet).&#xD;
&#xD;
              27. Have had a tattoo or body piercing within 30 days prior to drug administration.&#xD;
&#xD;
              28. Have clinically significant findings in vital signs measurements.&#xD;
&#xD;
              29. Systolic blood pressure increase or decrease in value by more than 20 mmHg and/or&#xD;
                  diastolic blood pressure decrease in value by more than 10 mmHg from supine or&#xD;
                  sitting to standing position.&#xD;
&#xD;
              30. Have clinically significant findings in a 12-lead ECG.&#xD;
&#xD;
              31. Have clinically significant abnormal laboratory values.&#xD;
&#xD;
              32. Have significant diseases.&#xD;
&#xD;
              33. Have clinically significant findings from a physical examination.&#xD;
&#xD;
              34. Use of any enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism&#xD;
                  or alter gastrointestinal pH/movement (e.g., omeprazole, ranitidine) within 30&#xD;
                  days prior to drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Faulknor, MD, CCFP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharma Medica Research Inc. Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Medica Research Inc</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5R 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naloxone</keyword>
  <keyword>Nasal</keyword>
  <keyword>Powder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opiate Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

